SandboxAQ has announced its biopharma molecular simulation division, AQBioSim, which aims to help biopharma companies and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company works with AstraZeneca, Sanofi, and UC San Francisco. SandboxAQ’s technology combines AI and quantum techniques to revolutionize drug discovery and development, reducing the time and cost of bringing life-saving treatments to the clinic. The company’s AQ-FEP software brings cutting-edge physics-based accuracy to the initial stages of the drug discovery pipeline, combining the precision of quantum mechanical equations with the speed and power of AI on classical computing hardware.
SandboxAQ Announces Biopharma Molecular Simulation Division
SandboxAQ has officially announced its biopharma molecular simulation division, AQBioSim, after several years of stealth development. The division is working with biopharma companies and research institutions, including AstraZeneca, Sanofi, and UC San Francisco, to achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions.
“SandboxAQ is at the forefront of combining AI and quantum techniques to address large, enterprise challenges. SandboxAQ’s technology is revolutionizing the drug discovery and development process,”
Eric Schmidt, Chairman of the Board of SandboxAQ.
SandboxAQ’s technology combines AI and quantum techniques to revolutionise drug discovery and development. Initial customer milestones show that these technologies can decrease the time and cost of developing new therapies and de-risk drug portfolios before entering preclinical and clinical stages.
AQ-Powered Solutions Accelerate Drug Discovery and Development
Nadia Harhen, leader of the AQBioSim division, said that SandboxAQ’s AQ-powered solutions accelerate drug discovery and development, mitigating its slow, complex, and error-prone nature. By shortening the discovery funnel, de-risking portfolios, and uncovering winning formulas earlier, the company empowers biopharma companies and research institutions to prioritise promising compounds, accelerate therapy development, extend patent lifetimes, drive revenue growth, and get cures to patients faster.
The technologies were leveraged by collaborating with UCSF’s Institute for Neurodegenerative Diseases to apply AI-powered simulation to identify potential therapies for neurodegenerative disorders rapidly. SandboxAQ’s proprietary Absolute Free Energy Perturbation (AQ-FEP) software was used to generate thousands of predictions of molecular interactions, leading to some exciting new compounds.
Cutting-Edge Physics-Based Accuracy in Drug Discovery Pipeline
SandboxAQ’s unique AQ-FEP software brings cutting-edge physics-based accuracy to the initial stages of the drug discovery pipeline. The company’s physicists, biologists, and computational and medicinal chemists have developed highly effective strategies to scale up quantum chemical simulations using massively parallel classical hardware.
These tools catalyze a suite of drug discovery solutions that combine the accuracy of quantum mechanical equations with the speed and power of AI available on classical computing hardware. Subsequent advancements include large-scale molecular dynamics simulations able to handle complex, undruggable targets.
Praise from Prominent Researchers
Prominent researchers have praised SandboxAQ’s approach and ability to accelerate drug discovery. Dr Siddhartha Mukherjee, the staff cancer physician at Columbia University Medical Center and Pulitzer prize winner, said that SandboxAQ is unique and the only partner he has seen deliver first-in-class molecules. Their ability to do meaningful quantum chemistry computation on today’s hardware is critical to the first principles approach needed in oncology and other major conditions.
Transforming Virtual Screening Campaign Execution
Dr Klaus Klumpp, co-founder and president of Riboscience, said their partnership with SandboxAQ accelerates drug candidate identification and optimization on novel targets within the Riboscience portfolio. SandboxAQ’s unprecedented large-scale absolute free energy perturbation solution is transforming their virtual screening campaign execution and allowing them to profile in-silico more than 20,000 ligands per day.
Impact on Biopharma and Life Sciences
Dr Kristin Gilkes, EY Global Quantum Leader, said that SandboxAQ’s AI-powered quantum technologies continue to revolutionise and disrupt industries. Still, few will experience such a transformative impact as biopharma and life sciences. The company seeks out the most demanding challenges. It applies technology and expertise to deliver impactful solutions, significantly advancing R&D for undruggable illnesses like cancer and Alzheimer’s that have confounded the industry for decades.
Paul Hudson, CEO of Sanofi, said, “We are very interested in SandboxAQ’s work to revolutionize drug discovery and development via in-silico simulation of molecular interactions using AI and quantum technologies. SandboxAQ’s leapfrog technology could significantly impact both preclinical and clinical development of drugs, and we look forward to seeing how it could support us in delivering life-changing treatments to patients worldwide faster.”
“Our AQ-powered solutions accelerate the drug discovery and development process, mitigating its slow, complex, and error-prone nature,”
Nadia Harhen, leader of the AQBioSim division.
“Neurodegenerative diseases are enormously complex and defy standard drug design,”
Stanley B. Prusiner, MD, who leads the UCSF Institute for Neurodegenerative Diseases.
Dr. Siddhartha Mukherjee, staff cancer physician at Columbia University Medical Center and Pulitzer prize winner, said, “SandboxAQ is unique and the only partner that I’ve seen deliver on first-in-class molecules. Their ability to do meaningful quantum chemistry computation on today’s hardware is critical to the first principles approach needed in oncology and other major conditions.”
“We are excited about our partnership with SandboxAQ where we are accelerating drug candidate identification and optimization on novel targets within the Riboscience portfolio,”
Dr. Klaus Klumpp, co-founder and president of Riboscience
“SandboxAQ’s AI-powered quantum technologies continue to revolutionize and disrupt industries, but few will experience such a transformative impact as biopharma and life sciences,”
Dr Kristin Gilkes, EY Global Quantum Leader
Executive Summary
SandboxAQ has launched its biopharma molecular simulation division, AQBioSim, which uses AI and quantum technologies to accelerate drug discovery and development for treatments such as cancer and Alzheimer’s. Collaborating with companies like AstraZeneca and Sanofi, SandboxAQ’s technology aims to reduce the time and cost of bringing life-saving therapies to patients.
- SandboxAQ announces its biopharma molecular simulation division, AQBioSim, which aims to accelerate drug discovery and development using AI and quantum technologies.
- AQBioSim is working with biopharma companies and research institutions, including AstraZeneca, Sanofi, and UC San Francisco, to develop treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions.
- Paul Hudson, CEO of Sanofi, and Eric Schmidt, Chairman of the Board of SandboxAQ, express their support for SandboxAQ’s technology and potential to revolutionize drug development and bring life-saving treatments to patients faster.
- Nadia Harhen, leader of the AQBioSim division, highlights the benefits of AQ-powered solutions in accelerating therapy development, extending patent lifetimes, driving revenue growth, and getting cures to patients faster.
- SandboxAQ’s proprietary Absolute Free Energy Perturbation (AQ-FEP) software was used in collaboration with UCSF’s Institute for Neurodegenerative Diseases to generate thousands of predictions of molecular interactions, leading to new compounds.
- Dr Siddhartha Mukherjee, staff cancer physician at Columbia University Medical Center, and Dr Klaus Klumpp, co-founder and president of Riboscience, praise SandboxAQ’s approach and ability to accelerate drug discovery.
- Dr Kristin Gilkes, EY Global Quantum Leader, highlights the transformative impact of SandboxAQ’s AI-powered quantum technologies on biopharma and life sciences.